Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP007 in Advanced Solid Tumors
NCT07800936Phase 1Recruiting
- Sponsor
- Parr Biotechnology
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sitmutolimod in solid tumor, sponsored by Parr Biotechnology. Primary endpoints: Dose-Limiting Toxicity at 1 year, Adverse Events at 2 years and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
sitmutolimod
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07800936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800936.